China¡¯s National Health Commission (NHC) recently responded to a deputies¡¯ proposal on ¡°Lifting Restrictions on Diagnostic Testing Services in Clinics to Promote the Implementation of Tiered Healthcare¡±: ..

Thermo Fisher Scientific, the world leader in serving science, has introduced the Applied Biosystems™ SwiftArrayStudio™ Microarray Analyzer, designed for fast and scalable sample analysis. In conjunction with two new arrays ¨C the Applied Biosystems Axiom™ PharmacoPro™ Array and the Applied Biosystems Axiom PangenomePro Array ¨C the analyzer combines four key genotyping processes into a single, integrated device, enabling researchers to cover the widest range of populations for Genome-Wide Association Studies (GWAS) and accelerate breakthrough discoveries in pharmacogenomics that will help drive the future of precision medicine forward.

Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2025.

OSR Holdings, Inc. (NASDAQ: OSRH) today announced that it has executed a definitive agreement to acquire Woori IO Co., Ltd. ("WORIO"), a pioneer in noninvasive glucose monitoring (NIGM), via a comprehensive share exchange. The acquisition reinforces OSRH's dedication to advancing biomedical innovation by adding a potential breakthrough technology for diabetes care, bringing truly needle-free glucose monitoring closer to patients globally and promising a safer, more convenient and accurate alternative to currently available technologies.

China leads the world in AI research publications related to the global medical device field over the past five years, according to a latest industrial white paper.

New Blood Coagulation Items In terms of the domestic IVD markets of hemostasis and thrombosis, the special testing items are gradually promoted and popularized in domestic medical institutions. The Grade III hos..

Wantai Biopharm Launches iMoD Smart Laboratory System Integrated with DeepSeek Technology Amid the accelerating wave of digital transformation in healthcare, Wantai Biopharm has officially launched the la..

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States Food and Drug Administration (FDA) has cleared its Elecsys pTau181 test, the only blood-based biomarker (BBM) test indicated as an aid in the initial assessment for Alzheimer¡¯s disease and other causes of cognitive decline in the primary-care setting. The Elecsys pTau181 test is intended for patients ages 55 and older presenting with signs, symptoms or complaints of cognitive decline. It measures phosphorylated Tau (pTau) 181 protein in human plasma, a key biomarker for Alzheimer¡¯s pathology, including amyloid plaque and tau aggregate pathology.

Private equity group Warburg Pincus is nearing a deal to take a large minority stake in French diagnostics group Sebia, which values the business at €5.4bn, according to people familiar with the matter.

Roche announced its strategic collaboration with the Office for Attracting Strategic Enterprises (OASES) to accelerate healthcare innovation and strengthen Hong Kong's role as a leading hub for life sciences and medical technology in the Asia Pacific region.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the Verona Pharma plc (Nasdaq: VRNA) (¡°Verona Pharma¡±) acquisition. Verona Pharma is now a wholly-owned subsidiary of Merck and the American Depositary Shares (ADS) of Verona Pharma will no longer be listed or traded on the Nasdaq Global Market.

Siemens Healthineers and the National University Hospital (NUH) Singapore have announced a strategic research collaboration to advance diagnostic solutions for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which affects nearly 40% of adults in Singapore ¡ª a prevalence that is higher than the global average of 30.05%.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Opentrons Labworks, Inc., recognized worldwide for accessible lab automation with more than 10,000 robotic systems deployed, today announced a multi-year collaboration. Together, BD and Opentrons will integrate robotic liquid-handling capabilities into BD single-cell multiomics instruments, automating critical experimental steps to accelerate and scale disease research and drug development.

Bio-Rad Laboratories has obtained the CE mark for next-generation versions of its Specialty Immunoassay Plus quality control reagents, the firm said Wednesday.

Roche (SIX: RO, ROG; OTCQX: RHHBY), in collaboration with KlinRisk, Inc., has received the CE-mark for the first AI-based risk stratification tool to assess progressive decline in kidney function. This milestone allows Roche to introduce the Chronic Kidney Disease (CKD) algorithm panel on its navify® Algorithm Suite to support care across all stages of the CKD care pathway. The panel includes the new Kidney Klinrisk Algorithm - for early risk assessment of adults diagnosed with CKD as well as adults with diabetes or hypertension at elevated risk for kidney function decline - alongside the established CE-marked Kidney KFRE Algorithm (KFRE) for managing later disease stages of CKD.